Page 3 - Pharmaceutical

PharmEasy founders step back to launch new venture in consumer space

Siddharth Shah, chief executive officer (CEO) and managing director (MD) of PharmEasy has also invested in the new venture in his personal capacity

Sun Pharma's unit Taro to acquire 100% stake in Antibe Therapeutics

The acquisition is expected to be completed before March 7, 2025, subject to approval from the Ontario Superior Court of Justice

PAG acquires majority stake in Pravesha Industries for $200 million

PAG had earlier acquired Manjushree Technopack for $1bn

Lupin receives US FDA tentative approval for Ivacaftor Oral Granules

These granules, available in 25 mg, 50 mg, and 75 mg per unit dose packets, are a generic equivalent of Kalydeco Oral Granules

Lupin gets clearance from USFDA for its Pithampur manufacturing facility

Lupin, headquartered in Mumbai, India, is a global pharmaceutical player with products distributed in over 100 markets

Assembly lines adopt flexible robotics to meet rising consumer expectations

These systems can be deployed across various industries ranging from pharmaceuticals, and consumer goods to the automotive sector

Budget wishlist: Pharma firms seek simplified taxes, stronger PLI scheme

Among other demands is the removal of Section 194R, related to marketing samples, which would ease business operations

Pharmed Ltd chairman emeritus Krishan Kumar Aurora passes away at 88

Krishan Kumar Aurora, chairman emeritus of Pharmed Limited and BioPlus Group, passed away on December 23 at 88. He began his career in 1961 with Smith Kline & French, rising to VP for Southeast Asia

Despite short-term blip, Sun Pharma remains favourite among investors

According to Bloomberg, 30 of 41 analysts are bullish on Sun Pharma, while the remaining seven have a neutral rating and only 4 are bearish

Pharma major Cipla not in the pink of health; growth challenges galore

Brokerages slash target price after subdued Q2 show

Navigating Regulatory Challenges: The Role of Experts in Reducing QC Testing Errors

.

Entod Pharma meets DCGI, issues clarification over eye drop 'claims'

Move comes after drug regulator had suspended nod granted to firm to manufacture, sell PresVu eye drops

Indian pharma sector set for 8-10% growth this fiscal: CRISIL Ratings

The sector is expected to benefit from steady cash flows and low financial leverage, which will help maintain stable credit profiles, even as pharma cos pursue acquisitions in niche therapeutic areas

Akums Drugs gets patent for formulation to manage sickle cell disease

Akums Drugs and Pharmaceuticals on Friday said it has received patent for a formulation for Sickle Cell Disease (SCD). The company has received a patent from India patent office for its room temperature stable oral suspension of Hydroxyurea, a formulation aimed at managing SCD. "Our constant endeavor is to work on affordable medicines for Orphan Drugs and reduce dependency on imported medicines ensuring patient safety from rare diseases with timely and necessary treatment," Akums Managing Director Sanjeev Jain said in a statement. SCD, a genetic blood disorder, leads to severe health complications such as anaemia, frequent pain episodes and other debilitating symptoms, affecting millions worldwide, especially in India and Africa. Akums said its formulation will come at a fraction of the cost of imported Hydroxyurea solution.

Domestic formulations biz expected to grow 9-10% over next decade: Glenmark

The drug formulations market in India is expected to grow at a CAGR of 9-10 per cent over the next decade with Jan Aushadhi outlets anticipated to emerge as a much stronger player in the country, according to Glenmark Pharmaceuticals. The domestic formulations market is estimated to be at Rs 2 lakh crore, with a growth rate of 11 per cent over the past two decades. "It is projected that the domestic formulations market will maintain a compound annual growth rate (CAGR) of 9-10 per cent over the next decade," the Mumbai-based drug maker said in its Annual Report for 2023-24. As the Trade Generics and Jan Aushadhi channels expand, it is anticipated that these channels could collectively contribute 30 per cent to the market volume in ten years, it stated. The Jan Aushadhi initiative aims to enhance access to cost-effective, unbranded generics by scaling up to 25,000 franchise pharmacies by 2026, it said. "It is estimated that Jan Aushadhi procurement could account for 3-5 per cent o

Entod Pharma denies false claims in media regarding PresVu Eye Drops

The company further mentioned that the opinions and claims printed in news stories do not represent Entod Pharmaceuticals

Shilpa Medicare hits fresh high on successful trial of liver fibrosis drug

Shares of Shilpa Medicare were trading at Rs 733.15, up by nearly Rs 36, or 5.15 per cent on the BSE. In contrast, the 30-stock BSE Sensex was trading at 81,714 levels, up 0.77 per cent.

US FDA approves first nasal spray from ARS Pharmaceuticals' for allergies

Neffy's approval is based on 4 studies in 175 healthy adults without anaphylaxis that measured epinephrine concentrations in blood following administration of neffy

GSK Pharma Q1 FY25 results: Net profit rises 37%, revenue up 6.9%

GSK Pharma's stocks were up by 2.49 per cent, ending the day's trade at Rs 2,824.45 apiece on the Bombay Stock Exchange (BSE)

Pharma groups criticise plan to shift nutraceuticals under drug authority

Pharmaceutical industry is urging government to halt the transfer of nutraceutical oversight from FSSAI to the drug regulatory authority, citing potential market impact